Quercetin-induced inhibition and synergistic activity with cisplatin - a chemotherapeutic strategy for nasopharyngeal carcinoma cells

被引:64
作者
Daker, Maelinda [1 ]
Ahmad, Munirah [1 ]
Khoo, Alan S. B. [1 ]
机构
[1] Inst Med Res, Mol Pathol Unit, Kuala Lumpur 50588, Malaysia
关键词
Cell proliferation; Chemotherapy; Cisplatin; Nasopharyngeal carcinoma; Quercetin; Synergism; FATTY-ACID SYNTHASE; FLAVONOID QUERCETIN; PHARMACOKINETICS; BIOAVAILABILITY; PROLIFERATION; APOPTOSIS; PHASE;
D O I
10.1186/1475-2867-12-34
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Nasopharyngeal carcinoma (NPC) is a unique tumour of epithelial origin with a distinct geographical distribution, genetic predisposition and environmental as well as dietary influence as aetiological factors. Standard NPC treatment regimes, such as radiotherapy and concurrent chemotherapy with cytotoxic drugs, can produce undesirable complications often associated with significant toxicity. Here, we report the effects of a widely distributed flavonoid, quercetin, on cell proliferation, apoptosis and cell cycle arrest. The effects of combining quercetin and cisplatin on human NPC cells were explored. Methods: Cell proliferation was monitored by the dynamic, impedance-based cell analyzer (xCELLigence system) and the MTS assay. Ki67 proliferation antigen and fatty acid synthase (FASN) level was examined by Western blotting. Flow cytometry was also carried out to study the effects of quercetin on cell cycle and apoptosis status. Results: At 100 mu M, quercetin inhibited cell proliferation and decreased expression of FASN and Ki67 antigen. Cell cycle analysis revealed a substantial increase in the proportion of cells in the G2/M phase. We also demonstrated the enhanced cytotoxic effects of quercetin treatment in concomitant with the chemotherapeutic drug, cisplatin, in cultured NPC cells. The combination index (CI) value of quercetin-cisplatin combination was < 1, indicating synergism. Conclusions: Our study showed that quercetin exhibited synergistic effects with cisplatin against NPC cells. Dose-reduction index (DRI) values > 1 implied the possibility of reducing the cisplatin dosage required to treat NPC, with the addition of quercetin. In turn, this could reduce the risk of cisplatin-associated toxicity. The potential of combining quercetin with cisplatin as a chemotherapeutic strategy for treatment of NPC should be explored further.
引用
收藏
页数:8
相关论文
共 31 条
  • [1] Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity
    Brusselmans, K
    Vrolix, R
    Verhoeven, G
    Swinnen, JV
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (07) : 5636 - 5645
  • [2] Authentication of nasopharyngeal carcinoma tumor lines
    Chan, Sylvia Yat-Yee
    Choy, Kwong-Wai
    Tsao, Sai-Wah
    Tao, Qian
    Tang, Tan
    Chung, Grace Tin-Yun
    Lo, Kwok-Wai
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (09) : 2169 - 2171
  • [3] Quercetin: A potential drug to reverse multidrug resistance
    Chen, Chen
    Zhou, Jane
    Ji, Chunyan
    [J]. LIFE SCIENCES, 2010, 87 (11-12) : 333 - 338
  • [4] Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO
  • [5] 2-F
  • [6] Nasopharyngeal carcinoma - Review of the molecular mechanisms of tumorigenesis
    Chou, Josephine
    Lin, Yu-Ching
    Kim, Jae
    You, Liang
    Xu, Zhidong
    He, Biao
    Jablons, David M.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (07): : 946 - 963
  • [7] Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    Chou, Ting-Chao
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 621 - 681
  • [8] Cross HJ, 1996, INT J CANCER, V66, P404
  • [9] Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2
    Dihal, Ashwin A.
    Woutersen, Ruud A.
    Van Ommen, Ben
    Rietjens, Ivonne M. C. M.
    Stierum, Rob H.
    [J]. CANCER LETTERS, 2006, 238 (02) : 248 - 259
  • [10] Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers
    Erlund, I
    Kosonen, T
    Alfthan, G
    Mäenpää, J
    Perttunen, K
    Kenraali, J
    Parantainen, J
    Aro, A
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (08) : 545 - 553